Diabetic Dyslipidemia: Epidemiology and Prevention of Cardiovascular Disease and Implications of Newer Therapies
- 296 Downloads
Purpose of Review
Dyslipidemia in patients with T2DM confers significant additional risk of adverse outcomes to patients with cardiovascular disease (CVD). These patients carry residual risk of adverse outcomes despite optimal management with conventional therapy such as lifestyle changes and statin therapy. The role of both nonstatin monotherapy in statin-intolerant patients and combination therapy with statins in patients with high risk of CVD events has been well studied. We sought to review the role of newer therapies in risk reduction in these patients.
Traditionally, non-statin options have included medications such as niacin, ezetimibe, fenofibrate, and n-3 fatty acids. Recently, drugs such as ezetimibe, inclisiran, and PCSK9 inhibitors have been studied with favorable results without an increased risk of developing new-onset diabetes. These medications hold the promise of increasing options to reduce cardiovascular risk in patients with T2DM.
The role of newer non-statin therapies in patients with diabetic dyslipidemia in combination with statins needs to be further explored.
KeywordsType 2 diabetes mellitus Dyslipidemia Statins Fibrates Ezetimibe Fish oil PCSK9 inhibitors Alirocumab Evolocumab Inclisiran
Compliance with Ethical Standards
Conflict of Interest
Haider J. Warraich and Jamal S. Rana declare that they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: •• Of major importance
- 8.Wong ND, Chuang J, Zhao Y, Rosenblit PD. Residual dyslipidemia according to low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B among statin-treated US adults: National Health and nutrition examination survey 2009-2010. J Clin Lipidol. 2015;9(4):525–32.CrossRefGoogle Scholar
- 10.Rock CL, Flatt SW, Pakiz B, Taylor KS, Leone AF, Brelje K, et al. Weight loss, glycemic control, and cardiovascular disease risk factors in response to differential diet composition in a weight loss program in type 2 diabetes: a randomized controlled trial. Diabetes Care. 2014;37(6):1573–80.CrossRefGoogle Scholar
- 21.Salami JA, Warraich HJ, Valero-Elizondo J, et al. National Trends in Nonstatin Use and Expenditures Among the US Adult Population From 2002 to 2013: Insights from medical expenditure panel survey. J Am Heart Assoc. 2018;7(2).Google Scholar
- 30.Taylor AJ, Sullenberger LE, Lee HJ, Lee JK, Grace KA. Arterial biology for the investigation of the treatment effects of reducing cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation. 2004;110(23):3512–7.CrossRefGoogle Scholar
- 35.Pearson TA, Denke MA, McBride PE, Battisti WP, Brady WE, Palmisano J. A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial. Mayo Clin Proc. 2005;80(5):587–95.CrossRefGoogle Scholar
- 40.•• Giugliano RP, Cannon CP, Blazing MA, et al. Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE-IT (improved reduction of outcomes: Vytorin efficacy international trial). Circulation. 2018;137(15):1571–82 This prespecified secondary analysis of IMPROVE-IT showed that the benefit of ezetimibe was almost exclusively experienced by patients with diabetes.CrossRefGoogle Scholar
- 41.Cannon CP, IMPROVE IT Investigators. IMPROVE-IT Trial: A Comparison of Ezetimibe/Simvastatin versus Simvastatin Monotherapy on Cardiovascular Outcomes After Acute Coronary Syndromes. Chicago: American Heart Association Scientific Sessions; 2014.Google Scholar
- 42.Writing C, Lloyd-Jones DM, Morris PB, et al. 2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: a report of the American College of Cardiology Task Force on clinical expert consensus documents. J Am Coll Cardiol. 2016;68(1):92–125.CrossRefGoogle Scholar
- 45.•• Sabatine MS, Leiter LA, Wiviott SD, et al. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. Lancet Diabetes Endocrinol. 2017;5(12):941–50 This prespecified substudy of FOURIER showed that evolocumab was safe and equally efficacious in diabetics and non-diabetics.CrossRefGoogle Scholar
- 49.Schwartz GG, Szarek M, Bhatt DL, Bittner V, Diaz R, Edelberg J, Goodman GG, Hanotin C, Harrington R, Jukema JW, Lecorps G, Moryusef A, Pordy R, Roe MT, White HD, Zeiher A, Steg G. Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab - ODYSSEY OUTCOMES. American College of Cardiology - 67th Scientific Sessions; 2018; Orlando.Google Scholar
- 51.Leiter L, Teoh H, Kallend D, Wright RS, Landmesser U, Wijngaard PL, Kastelein JJ, Ray KK. Inclisiran Lowers LDL-C and PCSK9 Irrespective of Diabetes Status without Worsening Glycemia. Diabetes. 2018; 67(Supplement 1). https://doi.org/10.2337/db18-337-OR. American Diabetes Association 2018.CrossRefGoogle Scholar
- 52.Lloyd-Jones DM, Morris PB, Ballantyne CM, Birtcher KK, Daly DD Jr, DePalma S, et al. 2017 focused update of the 2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: a report of the American College of Cardiology Task Force on expert consensus decision pathways. J Am Coll Cardiol. 2017;70(14):1785–822.CrossRefGoogle Scholar
- 54.Landmesser U, Chapman MJ, Farnier M, Gencer B, Gielen S, Hovingh GK, et al. European Society of Cardiology/European atherosclerosis society task force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk. Eur Heart J. 2017;38(29):2245–55.PubMedGoogle Scholar